Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 4 Composite 30-day composite end point of death or myocardial (re-) infarction in the four glycoprotein IIb/IIIa unstable ischemic syndrome trials. Efficacy data are not provided for the low-dose eptifibatide group PURSUIT and the tirofiban plus placebo group PRISM PLUS treatment arms, which were discontinued before completion of the trials. *p = 0.03 in PRISM PLUS did not reach the prespecified level of p = 0.025 for a three group trial;  Heparin use in PURSUIT was encouraged, but not mandated, and was administered to 89.9% and 89.7% of patients randomized to placebo and eptifibatide, respectively. PARAGON = Platelet IIb/IIIa Antagonism for the Reduction of Acute Coronary Syndrome events in the Global Organization Network; PRISM PLUS = Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs; PURSUIT = Platelet IIb/IIIa in Unstable Angina: Receptor Supression Using Integrilin Therapy.
|
